S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
Log in

LON:MXCTMaxCyte Share Price, Forecast & News

GBX 206
-6.00 (-2.83 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
202
Now: GBX 206
216
50-Day Range
167.50
MA: GBX 186.58
212
52-Week Range
95
Now: GBX 206
212
Volume626,640 shs
Average Volume1,951 shs
Market Capitalization£157.77 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
MaxCyte, Inc. operates as a cell-based medicines and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers, as well as transfection insourcing services. In addition, it develops CARMA, a messenger ribonucleic acid autologous platform for immune-oncology that enables manufacture and controllable delivery of next-generation chimeric antigen receptor engineered T/NK-cell therapies for a range of cancer indications, including solid tumors. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. has a cooperative research and development agreement with the National Institutes of Health's and National Institute of Allergy and Infectious Diseases to develop treatments for X-linked chronic granulomatous disease using gene correction leveraging CRISPR/Cas9; and a research agreement with Kite Pharma, Inc. to enable non-viral cell engineering. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland. MaxCyte, Inc. is a subsidiary of CASI Pharmaceuticals, Inc.
Read More
MaxCyte logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.65 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-301-9441700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£21.62 million
Cash FlowGBX 28.28 per share
Book ValueGBX 23.70 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap£157.77 million
Next Earnings DateN/A
OptionableNot Optionable

Receive MXCT News and Ratings via Email

Sign-up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter.

MaxCyte (LON:MXCT) Frequently Asked Questions

How has MaxCyte's stock been impacted by COVID-19 (Coronavirus)?

MaxCyte's stock was trading at GBX 150 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MXCT stock has increased by 37.3% and is now trading at GBX 206. View which stocks have been most impacted by Coronavirus.

Has MaxCyte been receiving favorable news coverage?

News coverage about MXCT stock has trended somewhat negative on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. MaxCyte earned a daily sentiment score of -1.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about MaxCyte.

Who are some of MaxCyte's key competitors?

What other stocks do shareholders of MaxCyte own?

Who are MaxCyte's key executives?

MaxCyte's management team includes the following people:
  • Mr. Douglas Arthur Doerfler, Co-Founder, CEO, Pres & Exec. Director (Age 63)
  • Mr. Ronald Evan Holtz, CFO, Sec. & Director (Age 61)
  • Mr. Maher Masoud, VP of Legal
  • Mr. Thomas Michael Ross, Exec. VP of Global Sales (Age 58)
  • Mr. Markus J. Hunkeler, VP of Marketing

What is MaxCyte's stock symbol?

MaxCyte trades on the London Stock Exchange (LON) under the ticker symbol "MXCT."

How do I buy shares of MaxCyte?

Shares of MXCT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is MaxCyte's stock price today?

One share of MXCT stock can currently be purchased for approximately GBX 206.

How big of a company is MaxCyte?

MaxCyte has a market capitalization of £157.77 million and generates £21.62 million in revenue each year.

What is MaxCyte's official website?

The official website for MaxCyte is www.maxcyte.com.

How can I contact MaxCyte?

MaxCyte's mailing address is 22 Firstfield Rd Ste 110, GAITHERSBURG, MD 20878-1795, United States. The company can be reached via phone at +1-301-9441700.

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.